Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study

Next Previous
X
Search
Trial Profile

Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Smoldering multiple myeloma
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 28 Mar 2024 Planned End Date changed from 1 Jun 2025 to 1 Jun 2028.
    • 12 Dec 2023 Results performing the first whole genome sequencing (WGS) analysis of treated HR-SMM (n=27) and comparing to (n=701) patients with NDMM from CoMMpass (NCT01454297), presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Follow-up data after all patients have completed lenalidomide maintenance to evaluate the durability of responses off therapy were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top